Methicillin-resistant Staphylococcus aureus bacteremia with elevated vancomycin minimum inhibitory concentrations

Alexandra G Mills; Amy C Dupper; Kieran I Chacko; Bremy Alburquerque; Devika Nadkarni; Ana Berbel Caban; Lindsey Fox; Melissa R Gitman; Ajay Obla; Harm van Bakel; Deena R Altman

doi:10.1017/ash.2023.163

Methicillin-resistant Staphylococcus aureus bacteremia with elevated vancomycin minimum inhibitory concentrations

Antimicrob Steward Healthc Epidemiol. 2023 May 2;3(1):e87. doi: 10.1017/ash.2023.163. eCollection 2023.

Authors

Affiliations

¹ Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
² Department of Genetics and Genomics Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
³ Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
⁴ Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York.
⁵ Icahn Genomics Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

Abstract

This case-control study of 25 cases with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia with vancomycin minimum inhibitory concentration (MIC) ≥ 2 µg/mL and 391 controls (MIC < 2 µg/mL) characterized the clinical characteristics, treatments, and outcomes associated with elevated vancomycin MIC. Elevated vancomycin MIC was associated with baseline hemodialysis, prior MRSA colonization, and metastatic infection.

Abstract

Grants and funding